GLP-1受体激动剂与SGLT-2抑制剂对2型糖尿病的心脏和肾脏益处:它们是并列的吗?

{"title":"GLP-1受体激动剂与SGLT-2抑制剂对2型糖尿病的心脏和肾脏益处:它们是并列的吗?","authors":"A. Singh, Viral N Shah","doi":"10.5603/dk.a2022.0037","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10386,"journal":{"name":"Clinical Diabetology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?\",\"authors\":\"A. Singh, Viral N Shah\",\"doi\":\"10.5603/dk.a2022.0037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10386,\"journal\":{\"name\":\"Clinical Diabetology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2022-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Diabetology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/dk.a2022.0037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/dk.a2022.0037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}